Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues:
Research and development programs	$ 7,051	$ 4,632	$ 18,542	$ 14,800
Product revenue	1,886		5,535
Total revenues	8,937	4,632	24,077	14,800
Operating expenses
Cost of product revenue	554		1,592
Research and development	10,866	9,260	28,692	21,841
Sales, general and administrative	11,527	4,331	28,591	11,415
Total operating expenses	22,947	13,591	58,875	33,256
Loss from operations	(14,010)	(8,959)	(34,798)	(18,456)
Other income (expense)
Interest and other income	174	48	512	127
Interest expense	(250)	(13)	(397)	(232)
Loss from change in fair value of warrant liabilities			(3,637)	(638)
Total other income (expense)	(76)	35	(3,522)	(743)
Net loss	(14,086)	(8,924)	(38,320)	(19,199)
Accretion of redeemable convertible preferred stock		(33)	(60)	(103)
Net loss attributable to Solazyme, Inc. common stockholders	$ (14,086)	$ (8,957)	$ (38,380)	$ (19,302)
Net loss per share attributable to Solazyme, Inc. common stockholders, basic and diluted	$ (0.24)	$ (0.77)	$ (1.15)	$ (1.70)
Weighted-average number of common shares used in loss per share computation, basic and diluted	59,508,371	11,708,321	33,271,816	11,363,717